We can’t show the full text here under this license. Use the link below to read it at the source.
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
How new diabetes drugs compare in protecting the heart and kidneys of patients with diabetic kidney disease
AI simplified
Abstract
SGLT2 inhibitors reduced the risk of a kidney-specific composite outcome by 26% compared to GLP-1RAs and by 36% compared to DPP-4 inhibitors.
- SGLT2 inhibitors are associated with a significant reduction in (MACE) by 18% compared to DPP-4 inhibitors.
- GLP-1 receptor agonists (GLP-1RAs) also reduce the risk of MACE by 18% compared to DPP-4 inhibitors.
- The risk of hospitalization for heart failure (HHF) was significantly reduced by 28% with SGLT2 inhibitors compared to GLP-1RAs.
- SGLT2 inhibitors lowered the risk of HHF by 41% compared to DPP-4 inhibitors.
- These findings support the use of SGLT2 inhibitors as a preferred treatment option for patients with .
AI simplified
Key numbers
26%
Reduction in Kidney-Specific Composite Outcome
SGLT2 inhibitors vs. GLP-1RAs
17%
Reduction in
SGLT2 inhibitors vs. placebo
36%
Reduction in Hospitalization for Heart Failure
SGLT2 inhibitors vs. placebo